BioMarin Pharmaceutical's Rare Disease Portfolio Supplemented By Amicus Acquisition Makes A Buy

BioMarin shares have declined more than 12% since January 2025, creating what the article frames as a potential buying opportunity. The thesis rests on VOXZOGO's growth prospects and Amicus's two approved therapies as future upside drivers. The piece is fundamentally constructive but presents no new clinical, regulatory, or earnings catalyst.

Analysis

BioMarin shares have declined more than 12% since January 2025, creating what the article frames as a potential buying opportunity. The thesis rests on VOXZOGO's growth prospects and Amicus's two approved therapies as future upside drivers. The piece is fundamentally constructive but presents no new clinical, regulatory, or earnings catalyst.